Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb CofiledCriticalBristol Myers Squibb Co
Publication of AR109237A1publicationCriticalpatent/AR109237A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Anticuerpos monoclonales aislados, en particular, anticuerpos humanos, que se fijan a IP-10 (proteína inducible por interferón g) con alta afinidad, inhiben la fijación de IP-10 a su receptor, inhiben el flujo de calcio inducido por IP-10 e inhiben la migración celular inducida por IP-10. También moléculas de ácido nucleico que codifican los anticuerpos de la presente, vectores de expresión, células huésped y métodos para expresar los anticuerpos de la presente solicitud. Además inmunoconjugados, moléculas biespecíficas y composiciones farmacéuticas que comprenden los anticuerpos de la presente. También métodos para inhibir la actividad de IP-10 usando los anticuerpos de la presente, que incluye métodos para tratar distintas enfermedades inflamatorias y autoinmunitarias.Isolated monoclonal antibodies, in particular, human antibodies, which bind to IP-10 (interferon g-inducible protein) with high affinity, inhibit the binding of IP-10 to its receptor, inhibit the flow of calcium induced by IP-10 and inhibit IP-10 induced cell migration. Also nucleic acid molecules encoding the antibodies of the present, expression vectors, host cells and methods for expressing the antibodies of the present application. In addition immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies herein. Also methods to inhibit IP-10 activity using the antibodies herein, which includes methods to treat various inflammatory and autoimmune diseases.
ARP170100749A2016-08-122017-03-27
ANTIBODIES AGAINST IP-10 AND ITS USES
AR109237A1
(en)
ISOLATED NUCLEIC ACID MOLECULES, ISOLATED POLYPEPTIDE MOLECULES, ISOLATED CAR MOLECULES, ANTI-EGFRVIII BINDING DOMAIN, VECTOR, CELL AND USE OF AN EFFECTIVE AMOUNT THEREOF, AND METHODS FOR PRODUCING A CELL AND PRODUCING A POPULATION OF CELLS MODIFIED BY RNA
antibody, nucleic acid, expression vector, host cell, composition, methods of treating a disease, to produce a bispecific antibody and to detect if cross-linking between cd40 and cd137 expressing cells occurs in a sample, use of a multispecific antibody and kit
"humanized antibody, antigen binding protein, nucleic acid molecule, expression vector, recombinant host cell, antibody or antigen binding protein, methods for producing an antigen binding protein and for treating a subject affected by an autoimmune or inflammatory disease, and, pharmaceutical composition. "
Antibody, peptide, nucleic acid molecule, vector, non-human animal or cell, composition, kit, uses of an antibody, peptide, molecule, or vector methods to determine if cd9 expressing cells are present in a sample to produce an antibody or functional part or functional equivalent, to treat and / or prevent a disorder associated with cd9 expressing cells and to produce a cd9 specific immune cell or a cd9 specific antibody, ex vivo method for determining if an individual is suffering from a cd9 positive cancer, immunogenic composition, and diagnostic kit?
BISPECIFIC ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, USES THEREOF, USES OF AN ANTI-CCL2 ANTIBODY, AND AN ANTI-LOXL2 ANTIBODY, OR FRAGMENTS AND KIT THEREOF